

**State of Oklahoma
Oklahoma Health Care Authority
Petition for Synagis Authorization**

Member Name: _____ Sex: _____ ID #: _____
 Date of birth: _____ Gestational age (GA): _____ weeks Current Age: _____ Months
 Birth Weight: _____ kg Current Weight: _____ kg Date Recorded: _____
 Dose received in hospital. Date: _____ **Prescriber Initials (Required)** _____ (confirming GA)

Drug Information

15 mg/kg IM. Only those doses that require greater than a vial's dose +10% may use the next vial size or an additional vial (e.g. 1-55 mg = 50 mg vial, 56-110 mg = 100 mg vial). The maximum duration of therapy is 5 doses, each dose to be given every 30 days.

Physician billing CPT code 90378 (50 mg/unit)
 Pharmacy billing 50 mg/0.5 ml: NDC: **60574411401** 100 mg/ml: NDC: **60574411301**

Billing Provider Information

Provider _____ Provider NPI _____
 Provider Phone: _____ Provider Fax: _____

Prescriber Information

Specialist: _____ Specialist NPI: _____
 Specialist Phone: _____ Specialist Fax: _____
 Primary Care Provider: _____ PCP address: _____
 PCP NPI: _____ PCP Phone: _____ PCP Fax: _____

Criteria

Member must be included in one of the following age groups at the beginning of the RSV season:

- Infants and children who are less than 24 months of age, born at 32 weeks' 0 days gestation or earlier and develop Chronic Lung Disease (CLD) of prematurity (require >21% oxygen supplementation for at least 28 days after birth) and who continue to require medical support (chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) during the 6 months before the start of the RSV season. Treatment/date received: _____
- Infants up to 12 months old with moderate-to-severe pulmonary hypertension or with acyanotic heart disease on medications to control congestive heart failure and will require cardiac surgical procedures. Please list medications: _____
- Infants less than 12 months of age, born at 29 weeks' 0 days gestation or earlier.
- Infants less than 12 months of age, with neuromuscular disease or congenital anomaly that impairs the ability to clear secretions from the upper airway because of ineffective cough.
Specify _____
- Infants less than 12 months of age, who undergo cardiac transplantation during RSV season.
Specify _____
- Infants less than 12 months of age with cystic fibrosis with clinical evidence of CLD and/or nutritionally compromised.
Specify _____
- Infants less than 24 months of age with cystic fibrosis with manifestations of severe lung disease or weight for length less than the 10th percentile.
Specify _____
- Infants less than 24 months of age, who are profoundly immunocompromised during RSV season.
Specify _____
- Additional Information: _____

Prescriber Signature (Required) _____ **Date** _____

Please do not send in chart notes. Specific information/documentation will be requested if necessary.

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy
 Pharmacy Management Consultants
 Product Based Prior Authorization Unit
 Fax: 1-800-224-4014

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return